

Making Cancer History®

REFRACTORY AND RESISTANT HSV INFECTIONS IN IMMUNOCOMPROMISED PATIENTS: SYSTEMATIC REVIEW AND PROPOSED DEFINITIONS


Tali Shafat, MDRoy F Chemaly, MD, MPHDepartment of Infectious Diseases, Infection Control, and Employee Health
The University of Texas MD Anderson Cancer Center
Houston Tx, USA




Introduction

Making Cancer History®

Herpes simplex virus (HSV) infection is one of the most common viral infections worldwide



Prolonged use of antivirals in immunocompromised patients



Resistant strains emerged

HSV infections burden in USA

Seropositivity is **40-50%** in adults (2018)

20-25% are symptomatic with orofacial or genital lesions

Ocular disease annual incidence is 6.8 to 31 cases per 100,000

Encephalitis annual incidence is 1 case per 100,000-150,000

Pneumonitis, hepatitis - rare

HSV-1


Seropositivity is **10-15%** in those who are sexually active (2018)

10-15% are symptomatic with anogenital lesions

HSV-2

Whitley R et al. Clinical management of herpes simplex virus infections: past, present, and future. F1000Res. 2018 Oct 31;7:F1000 Faculty Rev-1726. doi: 10.12688/f1000research.16157.1

McQuillan G et al. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14-49: United States, 2015-2016. NCHS Data Brief. 2018 Feb;(304):1-8. PMID: 29442994.




to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459-72.

Host factors	Viral factors	Antiviral therapy
Haploidentical, allogeneic,	Recurrent infections	Nucleoside analogs
or cord blood HCT		exposure
HCT for Relapsed	Ongoing viral replication	Prolonged antiviral
hematologic malignancies		treatment
Hematologic malignancies	HSV-2	Inadequate / intermittent
		treatment
Graft versus host disease		
SOT (heart and lung)		
Myelofibrosis		
HIV/AIDS		
Congenital		
immunodeficiency		
syndromes		
Anti-TNF therapy		
Keratitis		

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center

Making Cancer History®



Nath AK, Thappa DM. Newer trends in the management of genital herpes. Indian J Dermatol Venereol Leprol. 2009 Nov-Dec;75(6):566-74. doi: 10.4103/0378-6323.57716. PMID: 19915235.

Clinical Characteristics and Outcomes



Mostly mucocutaneous disease


- Prolonged, recurrent and extensive lesions
- Abnormal lesion appearance ulcerative, hypertrophic, pseudotumor-like lesions
- Dissemination to invasive disease (CNS, lung, liver) is rare

In HCT recipients → prolonged anti-viral therapy, recurrent infections, renal failure, increased risk of hospitalization

• Toxic alternative treatment options (Foscarnet, Cidofovir)

Tandon S et al. Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. Dermatol Ther. 2017 May;30(3). doi: 10.1111/dth.12479. Anton-Vazquez V et al. Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients. J Clin Virol. 2020 Jul;128:104421. doi: 10.1016/j.jcv.2020.104421. Ariza-Heredia EJ et al. Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int. 2018 Jun;31(6):639-648. doi: 10.1111/tri.13142. Patel D et al. Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation. Clin Transplant. 2014 Jan;28(1):1-5. doi: 10.1111/ctr.12227.

Refractory / resistance HSV infection diagnosis




Phenotyping

- Plaque reduction assay
- The concentration of drug that reduces the plaque number by 50% (IC50)
- \circ Slow
- Subjective

Genotyping

- Detection of specific mutations in UL23, UL30
- Sanger sequencing
- Next generation sequencing


• Polymorphism!





Systematic review of resistant / refractory HSV infections in immunocompromised hosts

- PubMed and Embase databases
- "Herpes simplex virus or HSV", "Resistan*", "Refractory" and "Immunocompromised" "Immunosuppress*", "Immunodeficien*, excluding reviews and animal studies
- 487 titles were screened
- 196 papers reviewed
- Only 4 RCT's from the 1990'
- Current phase III pritelivir (AiCuris) RCT definitions



Pritelivir protocol definitions:




 ACV-R mucocutaneous HSV episodes: Clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion

 Clinical failure definition: No improvement after oral or IV doses for at least 7 days at doses equivalent to or greater than the local agency approved high doses of acyclovir, valacyclovir or famciclovir

Time out





refractory HSV infection clinically?



Suggested definitions for <u>Refractory</u> <u>Mucocutaneous</u> HSV infection



Making Cancer History®


OR

 Breakthrough mucocutaneous infection on current therapy <u>excluding</u> prophylaxis or suppressive anti-viral therapy



Suggested definition for <u>Recurrent</u> HSV infection

 New HSV-related infection (mucocutaneous lesion or other) that emerges at least 2? 4? weeks after resolution of a previous HSVrelated infection episode





Take home messages

- Refractory/resistant HSV infections are not uncommon in immunocompromised population
- Consensus definitions for refractory and resistant HSV infection are needed for clinical trials and research use
- Genotyping methods are improving and allowing rapid detection of mutations
- New treatment options are needed